Brought to you by 
Blend Therapeutics assumes new name Tarveda, shifts focus, raises $38mm through Series C round
29 Feb 2016
Executive Summary
Tarveda Therapeutics Inc. (formerly Blend Therapeutics; developing miniaturized biologics for cancer) raised $38mm in a Series C round co-led by new investor Novo AS and returning buyer New Enterprise Associates (which both join the company's board). Other existing backers also participated, including Flagship Ventures, NanoDimension, and Eminent Venture Capital.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Blend Therapeutics assumes new name Tarveda, shifts focus, raises $38mm through Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice